Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single ‐arm, open‐label phase 2 study

ConclusionsAzacitidine was safe and effective in Chinese patients with HR‐MDS. Clinical outcomes were comparable to those for primarily Caucasian patients in the phase 3 AZA‐001 study. Cmax differences between Chinese and North American patients were not associated with differences in TEAE frequency or severity. No initial azacitidine dose adjustment is required for Chinese patients with HR‐MDS. (Source: Asia-Pacific Journal of Clinical Oncology)

from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2CFqZcq